Company intelligence / Profile preview

Onconostic Technologies-3N Diagnostics Group

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

The VERESCA FOXC1 IHC test distinguishes aggressive vs. non-aggressive cancer subtypes via FOXC1 expression; it is clinically validated in over 17,000 patients, CE marked, demonstrated in Phase 3 trials to predict survival benefits for specific treatments, and available in the EU and CLIA labs[2][4][7].

Therapeutic areas: Oncology
Modalities: Diagnostic assay (Immunohistochemistry)
Industry: Protein Biomarker Diagnostics

Partnerships

GEICAM Spanish Breast Cancer Group (for clinical trials)[4][5][7]

Beyond the preview

Go deeper on Onconostic Technologies-3N Diagnostics Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onconostic Technologies-3N Diagnostics Group.

Explore the full profile